Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, CA.
Institute of Pathology, University of Greifswald, Greifswald, Germany.
Gastroenterology. 2014 Sep;147(3):690-701. doi: 10.1053/j.gastro.2014.05.004. Epub 2014 May 14.
BACKGROUND & AIMS: Aberrant activation of β-catenin and Yes-associated protein 1 (Yap1) signaling pathways have been associated with the development of multiple tumor types. Yap functions as a transcriptional coactivator by interacting with TEA domain DNA binding proteins. We investigated the interactions among these pathways during hepatic tumorigenesis.
We used immunohistochemical analysis to determine expression of β-catenin and Yap1 in liver cancer specimens collected from patients in Europe and the United States, consisting of 104 hepatocellular carcinoma, 62 intrahepatic cholangiocarcinoma, and 94 hepatoblastoma samples. We assessed β-catenin and Yap1 signaling and interactions in hepatoblastoma cell lines ((HuH6, HepG2, HepT1, HC-AFW1, HepG2, and HC-AFW1); proteins were knocked down with small interfering RNAs, and effects on proliferation and cell death were measured. Sleeping beauty-mediated hydrodynamic transfection was used to overexpress constitutively active forms of β-catenin (ΔN90/β-catenin) and Yap1 (YapS127A) in livers of mice; tissues were collected, and histological and immunohistochemical analyses were performed.
We observed nuclear localization of β-catenin and Yap1 in 79% of hepatoblastoma samples but not in most hepatocellular carcinoma or intrahepatic cholangiocarcinoma samples. Yap1 and β-catenin coprecipitated in hepatoblastoma but not hepatocellular carcinoma cells. Small interfering RNA-mediated knockdown of Yap1 or β-catenin in hepatoblastoma cells reduced proliferation in an additive manner. Knockdown of Yap1 reduced its ability to coactivate transcription with β-catenin; β-catenin inhibitors inactivated Yap1. Overexpression of constitutively active forms of Yap1 and β-catenin in mouse liver led to rapid tumorigenesis, with 100% mortality by 11 weeks. Tumor cells expressed both proteins, and human hepatoblastoma cells expressed common targets of their 2 signaling pathways. Yap1 binding of TEA domain factors was required for tumorigenesis in mice.
β-catenin and the transcriptional regulator Yap1 interact physically and are activated in most human hepatoblastoma tissues; overexpression of activated forms of these proteins in livers of mice leads to rapid tumor development. Further analysis of these mice will allow further studies of these pathways in hepatoblastoma pathogenesis and could lead to the identification of new therapeutic targets.
β-连环蛋白和 Yes 相关蛋白 1(Yap1)信号通路的异常激活与多种肿瘤的发生发展有关。 Yap 通过与 TEA 结构域 DNA 结合蛋白相互作用,作为转录共激活因子发挥作用。我们研究了这些通路在肝肿瘤发生过程中的相互作用。
我们使用免疫组织化学分析方法,检测了来自欧洲和美国的 104 例肝细胞癌、62 例肝内胆管癌和 94 例肝母细胞瘤患者的肝癌标本中β-连环蛋白和 Yap1的表达。我们评估了肝母细胞瘤细胞系(HuH6、HepG2、HepT1、HC-AFW1、HepG2 和 HC-AFW1)中β-连环蛋白和 Yap1信号通路及其相互作用,用小干扰 RNA 敲低蛋白,测量增殖和细胞死亡的影响。用睡美人介导的水力转染在小鼠肝脏中过表达组成型激活形式的β-连环蛋白(ΔN90/β-连环蛋白)和 Yap1(YapS127A);收集组织,进行组织学和免疫组织化学分析。
我们观察到 79%的肝母细胞瘤标本中存在β-连环蛋白和 Yap1的核定位,但大多数肝细胞癌或肝内胆管癌标本中不存在。 Yap1 和 β-连环蛋白在肝母细胞瘤细胞中共同沉淀,但在肝细胞癌细胞中没有。肝母细胞瘤细胞中 Yap1 或 β-连环蛋白的小干扰 RNA 敲低以累加方式降低增殖。 Yap1 的敲低降低了其与β-连环蛋白共同激活转录的能力;β-连环蛋白抑制剂使 Yap1失活。组成型激活形式的 Yap1 和 β-连环蛋白在小鼠肝脏中的过表达导致快速肿瘤发生,11 周时死亡率达到 100%。肿瘤细胞表达这两种蛋白,人肝母细胞瘤细胞表达它们的两种信号通路的共同靶标。 Yap1 与 TEA 结构域因子的结合是小鼠肿瘤发生所必需的。
β-连环蛋白和转录调节因子 Yap1在大多数人类肝母细胞瘤组织中发生物理相互作用并被激活;这些蛋白的激活形式在小鼠肝脏中的过表达导致快速肿瘤发展。对这些小鼠的进一步分析将允许进一步研究这些通路在肝母细胞瘤发病机制中的作用,并可能导致新的治疗靶点的确定。